Radiation boosts CAR-T: new hope for tough lymphoma?

NCT ID NCT06768905

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a single dose of a targeted radiation drug (Iomab-B) before standard CAR-T cell therapy can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 participants will receive the radiation followed by CAR-T cells. Researchers are checking for safety, side effects, and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iomab-B (targeted radiation) followed by CAR-T cell therapy
What this could lead to: If it works, this could make CAR-T therapy safer and more effective for people with hard-to-treat lymphoma, potentially leading to longer remissions.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. The combination of radiation and cell therapy carries risks like severe immune reactions and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.